Vigil Neuroscience (VIGL) announced that Sanofi (SNY) has made a $40M strategic investment in the company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the company’s Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The company will use the proceeds to fund its research and development activities. In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation, or ROFN, for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the company’s small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer’s disease. Based on current projections, the company expects that the proceeds from Sanofi’s investment will extend its cash runway into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
- These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
- Vigil Neuroscience to Present in Upcoming June Investor Conferences
- Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
- Vigil Neuroscience reports Q1 EPS (50c), consensus (61c)